Patents by Inventor Barbara Robertson
Barbara Robertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002326Abstract: Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.Type: ApplicationFiled: June 27, 2023Publication date: January 4, 2024Inventors: Mathias FRANCOIS, Johannes ZUEGG, Jeroen OVERMAN, Sreeman Kumar MAMIDYALA, Angela Aguslyarti SALIM, Frank Roger FONTAINE, Matthew Allister COOPER, Robert John CAPON, Avril Alexis Barbara ROBERTSON
-
Publication number: 20230100768Abstract: Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.Type: ApplicationFiled: May 10, 2022Publication date: March 30, 2023Inventors: Mathias FRANCOIS, Johannes ZUEGG, Jeroen OVERMAN, Sreeman Kumar MAMIDYALA, Angela Aguslyarti SALIM, Frank Roger FONTAINE, Matthew Allister COOPER, Robert John CAPON, Avril Alexis Barbara ROBERTSON
-
Patent number: 11434190Abstract: Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.Type: GrantFiled: December 21, 2017Date of Patent: September 6, 2022Assignee: THE UNIVERSITY OF QUEENSLANDInventors: Mathias Francois, Johannes Zuegg, Jeroen Overman, Sreeman Kumar Mamidyala, Angela Aguslyarti Salim, Frank Roger Fontaine, Matthew Allister Cooper, Robert John Capon, Avril Alexis Barbara Robertson
-
Publication number: 20190337880Abstract: Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.Type: ApplicationFiled: December 21, 2017Publication date: November 7, 2019Inventors: Mathias FRANCOIS, Johannes ZUEGG, Jeroen OVERMAN, Sreeman Kumar MAMIDYALA, Angela Aguslyarti SALIM, Frank Roger FONTAINE, Matthew Allister COOPER, Robert John CAPON, Avril Alexis Barbara ROBERTSON
-
Patent number: 8415466Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.Type: GrantFiled: April 30, 2012Date of Patent: April 9, 2013Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Devin Leake, Barbara Robertson, Annaleen Vermeulen, Christina Yamada
-
Patent number: 8367318Abstract: The disclosure provides methods for inhibiting the activity of a miRNA cluster in a cell, and also for screening a cell for a phenotype(s) of interest resulting from inhibition of a miRNA cluster. The methods use a cluster pool which comprises at least one miRNA inhibitor specific for each miRNA in the miRNA cluster. MiRNA inhibitors are described that induce apoptosis in breast cancer cells and hence are useful in the treatment of breast cancer. The disclosure also provides pharmaceutical compositions which are useful for the treatment of breast cancer; methods for inducing the nuclear translocation of NF-?B in a breast cancer cell; methods for inducing the nuclear translocation of c-Jun in a breast cancer cell; method for inhibiting the nuclear translocation of NF-?B in a breast cancer cell; and methods for providing prognostic medical information relating to breast cancer progression.Type: GrantFiled: July 21, 2008Date of Patent: February 5, 2013Assignee: Dharmacon, Inc.Inventors: Anja Smith, Scott Baskerville, Devin Leake, Annaleen Vermeulen, Barbara Robertson, Anastasia Khvorova
-
Publication number: 20120259001Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.Type: ApplicationFiled: April 30, 2012Publication date: October 11, 2012Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Devin Leake, Barbara Robertson, Annaleen Vermeulen, Christina Yamada
-
Patent number: 8188060Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.Type: GrantFiled: February 10, 2009Date of Patent: May 29, 2012Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Devin Leake, Barbara Robertson, Annaleen Vermeulen, Christina Yamada
-
Patent number: 7935811Abstract: A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least a first siRNA which silences a first target gene. The gene silencing composition can be configured such that the at least first siRNA is capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the at least first siRNA can include a modification or a conjugate. The reverse transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like.Type: GrantFiled: November 18, 2005Date of Patent: May 3, 2011Assignee: Dharmacon, Inc.Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William S. Marshall, Anastasia Khvorova
-
Patent number: 7923207Abstract: A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least two siRNAs which silences at least a first target gene. The gene silencing composition can be configured such that the at least two siRNAs are each capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the siRNAs can include a hairpin structure, modification, or a conjugate. Also, the at least siRNAs can be rationally designed. The reverse transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like.Type: GrantFiled: November 18, 2005Date of Patent: April 12, 2011Assignee: Dharmacon, Inc.Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William S. Marshall, Anastasia Khvorova
-
Patent number: 7923206Abstract: A method of determining a cellular response to a biological agent can be preformed in the presence of gene silencing. Such a method can include the use of siRNA in order to silence various genes in the cell in order to monitor the cellular response to the biological agent when a gene has been silenced. Accordingly, the response of a cell having a silenced gene to a biological agent can be indicative of which genes may be responsible for normal or abnormal cellular responses to various synthetic and natural biological agents such as active agents or pathogens.Type: GrantFiled: November 18, 2005Date of Patent: April 12, 2011Assignee: Dharmacon, Inc.Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William S. Marshall, Anastasia Khvorova
-
Publication number: 20100273856Abstract: The disclosure provides methods for inhibiting the activity of a miRNA cluster in a cell, and also for screening a cell for a phenotype(s) of interest resulting from inhibition of a miRNA cluster. The methods use a cluster pool which comprises at least one miRNA inhibitor specific for each miRNA in the miRNA cluster. MiRNA inhibitors are described that induce apoptosis in breast cancer cells and hence are useful in the treatment of breast cancer. The disclosure also provides pharmaceutical compositions which are useful for the treatment of breast cancer; methods for inducing the nuclear translocation of NF-?B in a breast cancer cell; methods for inducing the nuclear translocation of c-Jun in a breast cancer cell; method for inhibiting the nuclear translocation of NF-?B in a breast cancer cell; and methods for providing prognostic medical information relating to breast cancer progression.Type: ApplicationFiled: July 21, 2008Publication date: October 28, 2010Applicant: DHARMACON INC.Inventors: Anja Smith, Scott Baskerville, Devin Leake, Annaleen Vermeulen, Barbara Robertson, Anastasia Khvorova
-
Publication number: 20100184209Abstract: The present invention provides compositions and methods for inhibiting gene silencing by the RNAi pathway. The RNAi inhibitors of the invention have a reverse complement (RC) region to the target molecule of interest (e.g., miRNA) in association with at least one flanking region coupled to either at the 3? or 5? end of the RC region. The flanking regions can be single-stranded or can have one or more regions of double stranded nucleic acid with or without a hairpin loop. The RNAi inhibitors described herein can inhibit endogenous targets, including but not limited to microRNAs, or piRNAs, or can be used to inhibit the effects of exogenously introduced molecules, such as synthetic siRNAs, siRNAs expressed from vector constructs (e.g., viral expression systems), or siRNAs generated by enzymatic methods. Inhibition is specific, potent, prolonged, and can be performed on a single target or multiple targets simultaneously.Type: ApplicationFiled: February 16, 2007Publication date: July 22, 2010Applicant: Dharmacon, Inc.Inventors: Annaleen Vermeulen, Barbara Robertson, Scott Baskerville, Christina Yamada, Devin Leake, Yuriy Fedorov, Jon Karpilow, Anastasia Khvorova
-
Publication number: 20090280567Abstract: RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5? terminal sense nucleotides with 2?-O-alkyl groups and a label on the first 5? terminal sense nucleotide, in conjunction with at least one additional 2?-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2? fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5? terminal antisense nucleotide; or (ii) a first and second 5? terminal antisense nucleotide with 2?-O-alkyl modifications and at least one additional 2?-O-alkyl pyrimidine modified antisense nucleotide.Type: ApplicationFiled: June 17, 2009Publication date: November 12, 2009Applicant: DHARMACON, INC.Inventors: Devin Leake, Anastasia Khvorova, Yuriy Fedorov, Michael Owen Delaney, Barbara Robertson, Emily Anderson, Angela Reynolds
-
Publication number: 20090209626Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.Type: ApplicationFiled: February 10, 2009Publication date: August 20, 2009Applicant: Dharmacon, Inc.Inventors: Anastasia Khvorova, Devin Leake, Barbara Robertson, Annaleen Vermeulen, Christina Yamada
-
Publication number: 20070269889Abstract: RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5? terminal sense nucleotides with 2?-O-alkyl groups and a label on the first 5? terminal sense nucleotide, in conjunction with at least one additional 2?-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2? fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5? terminal antisense nucleotide; or (ii) a first and second 5? terminal antisense nucleotide with 2?-O-alkyl modifications and at least one additional 2?-O-alkyl pyrimidine modified antisense nucleotide.Type: ApplicationFiled: February 4, 2005Publication date: November 22, 2007Applicant: DHARMACON, INC.Inventors: Devin Leake, Anastasia Khvorova, Yuriy Fedorov, Michael Delaney, Barbara Robertson, Emily Anderson, Angela Reynolds
-
Publication number: 20060166234Abstract: An RTF testing plate can include at least a first control well including a substantially dry first control composition having at least a first control siRNA. The first control siRNA is capable of providing a first indication of the gene silencing efficacy. Additionally, the first control composition can be configured such that the first control siRNA is capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the first control well. The control siRNA can be any one of a transfection control siRNA, positive control siRNA, or negative control siRNA. Optionally, the total amount of control siRNA in the first control composition can be present in an amount for transfecting cells in only the first control well.Type: ApplicationFiled: November 18, 2005Publication date: July 27, 2006Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William Marshall, Anastasia Khvorova
-
Publication number: 20060115461Abstract: A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least a first siRNA which silences a first target gene. The gene silencing composition can be configured such that the at least first siRNA is capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the at least first siRNA can include a modification or a conjugate. The reverse transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like.Type: ApplicationFiled: November 18, 2005Publication date: June 1, 2006Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William Marshall, Anastasia Khvorova
-
Publication number: 20060110766Abstract: A method of determining a cellular response to a biological agent can be preformed in the presence of gene silencing. Such a method can include the use of siRNA in order to silence various genes in the cell in order to monitor the cellular response to the biological agent when a gene has been silenced. Accordingly, the response of a cell having a silenced gene to a biological agent can be indicative of which genes may be responsible for normal or abnormal cellular responses to various synthetic and natural biological agents such as active agents or pathogens.Type: ApplicationFiled: November 18, 2005Publication date: May 25, 2006Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William Marshall, Anastasia Khvorova
-
Publication number: 20060110829Abstract: A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least two siRNAs which silences at least a first target gene. The gene silencing composition can be configured such that the at least two siRNAs are each capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the siRNAs can include a hairpin structure, modification, or a conjugate. Also, the at least siRNAs can be rationally designed. The reverse transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like.Type: ApplicationFiled: November 18, 2005Publication date: May 25, 2006Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William Marshall, Anastasia Khvorova